Navellier & Associates Inc lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 62.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,345 shares of the company’s stock after selling 38,206 shares during the quarter. Navellier & Associates Inc’s holdings in IDEXX Laboratories were worth $3,651,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in IDXX. Zions Bancorporation acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $162,000. Benjamin F. Edwards & Company Inc. raised its position in IDEXX Laboratories by 1,000.0% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after buying an additional 1,000 shares during the last quarter. SignalPoint Asset Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $200,000. Ledyard National Bank raised its position in IDEXX Laboratories by 58.9% in the 4th quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock valued at $203,000 after buying an additional 480 shares during the last quarter. Finally, BB&T Securities LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $213,000. 86.02% of the stock is currently owned by institutional investors and hedge funds.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $183.94 on Thursday. The firm has a market capitalization of $15,957.41, a P/E ratio of 57.96, a price-to-earnings-growth ratio of 2.25 and a beta of 0.58. IDEXX Laboratories, Inc. has a 1 year low of $141.02 and a 1 year high of $198.73. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.04. The firm had revenue of $506.00 million for the quarter, compared to analyst estimates of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The business’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.58 EPS. sell-side analysts forecast that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.
A number of equities research analysts recently issued reports on IDXX shares. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 target price on the stock in a research report on Monday, February 5th. BidaskClub lowered IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Bank of America lifted their target price on IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Piper Jaffray Companies lifted their target price on IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Finally, Canaccord Genuity reissued a “buy” rating and issued a $210.00 target price on shares of IDEXX Laboratories in a research report on Monday, January 29th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $194.00.
In related news, Director Lawrence D. Kingsley purchased 1,000 shares of the stock in a transaction on Wednesday, February 14th. The shares were purchased at an average price of $178.05 per share, with a total value of $178,050.00. Following the transaction, the director now directly owns 4,558 shares of the company’s stock, valued at $811,551.90. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Giovani Twigge sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. Insiders have sold a total of 86,762 shares of company stock worth $15,202,484 in the last ninety days. Insiders own 2.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Navellier & Associates Inc Sells 38,206 Shares of IDEXX Laboratories, Inc. (IDXX)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/22/navellier-associates-inc-sells-38206-shares-of-idexx-laboratories-inc-idxx.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.